SPL Commences VivaGel Bacterial Vaginosis Prevention Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Starpharma`s VivaGel Phase 3 trials 60% enrolled
- SPL`s dendrimers improve efficacy of docetaxel in animals
- SPL receives FDA Special Protocol Assessment for BV Phase 3
- SPL Commences pivotal phase 3 VivaGel BV treatment trials
- Response to an ASX price query
Later from Starpharma
- Starpharma Expands Lilly Partnership
- Starpharma`s partner SSL acquired by Reckitt Benckiser
- Starpharma and Lilly Sign New Drug Delivery Collaboration
- Starpharma`s Bacterial Vaginosis Study gets FDA Clearance
- Successful completion of VivaGel study sexually active women
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma